We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Juno Therapeutics, Inc. (NASDAQ: JUNO) to Celgene Corporation (NASDAGS: CELG) for $87 per share.
The complaint concerns whether the Board of Juno Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Celgene Corporation is underpaying for Juno Therapeutics shares, thus unlawfully harming Juno Therapeutics shareholders.
To receive more information, please fill out the form.